News
Morphosys to take on CAR-Ts in NHL with promising antibody
Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a common form of non-Hodgkin lymphoma, saying that the phase 2 t
